Study Objectives: To investigate the activity of brown adipose tissue (BAT) in patients with type 1 narcolepsy during cold exposure using two separate scans of sympathetic and metabolic activity of BAT to evaluate whether orexin deficiency leads to altered nonshivering thermoregulation in narcolepsy.
Introduction
Type 1 narcolepsy is a chronic neurological disorder, which is characterized by excessive daytime sleepiness, disordered regulation of rapid eye movement (REM) sleep, cataplexy, i.e. sudden loss of muscle tone triggered by strong emotions in most of the patients, as well as sleep paralysis and hypnagogic hallucinations during sleep onset [1] . Overnight polysomnography (PSG) reveals fragmented light sleep and higher frequency of sleepwake transitions, and multiple sleep latency test (MSLT) shows a short time to fall asleep plus REM sleep. The disease afflicts 1 in 2000 individuals equally distributed between men and women with age of onset varying from early childhood to the 50s, with a large peak around 15 years of age [1, 2] . Type 1 narcolepsy is associated with low levels of orexin-A (also known as hypocretin-1) in the cerebrospinal fluid (CSF) reflecting a selective loss of orexinergic neurons in the lateral hypothalamus presumably caused by an autoimmune mechanism [3] [4] [5] . The disease shows a strong association with the genotype HLA-DQB1*06:02 which is carried by more than 98 per cent of the patients versus about 20 per cent in healthy individuals [1, 5] .
Patients with narcolepsy suffer from an autonomic dysfunction including changes in cardiovascular, sympathetic, and temperature regulation [6, 7] . Occurrence of lower values of arterial pressure, heart rate, and muscle sympathetic nerve activity has been reported in patients with narcolepsy, but only during wakefulness [8] . Conversely, heart rate, blood pressure, and sympathetic activity to muscles and skin in patients with narcolepsy were normal to high during sleep [9] [10] [11] [12] . Abnormal regulation of skin temperature in patients with narcolepsy was characterized by a combination of a higher distal skin temperature and a lower proximal skin temperature (reduced distal-proximal gradient), which in healthy participants is associated with the process of falling asleep [13, 14] . A recent study of the circadian rhythm and wake-sleep state-dependent modulation of body core temperature for 44 hr in patients with narcolepsy under controlled conditions showed that the daily body core temperature rhythm and modulation through sleep stages were comparable in patients and control participants [15] .
Brown adipose tissue (BAT) has been identified as playing a role in thermoregulation in hibernating animals and in human infants [16] . Until recently, it has been assumed that active BAT disappeared in humans approximately at adolescence. However, within the past decade, it has been recognized that adult humans still have active BAT located at the neck, most commonly in the supraclavicular region, but also frequently along the aorta in the mediastinum and the vertebral spine in the thorax [17] [18] [19] . Cold exposure increased the activity of BAT as demonstrated by 18 F-fluoro-deoxyglucose ( 18 F-FDG) positron emission tomography (PET) and computed tomography (CT) [20, 21] .
123
I-meta-iodo-benzyl-guanidine ( 123 I-MIBG) single photon emission computed tomography (SPECT) showed sympathetic stimulation of BAT in humans [20] .
Intracerebral ventricular administration of orexin-A activated BAT leading to increased body temperature in rats [22] . Using orexin knockout mice and orexin neuron-ablated mice, it was found that orexin neurons in the hypothalamus, but not orexin peptides per se, are indispensable for BAT thermogenesis induced by stress, prostaglandin E 2 , and cold exposure [23, 24] . The neural substrate for the influence of orexin neurons on BAT thermogenesis in the rat was identified by nanoinjection of orexin-A into the rostral raphe pallidus of medulla oblongata, the site of BAT sympathetic premotor neurons, which produced a large, sustained increase in BAT sympathetic outflow and thermogenesis [25] .
Several hormones and neurotransmitters in addition to norepinephrine and orexin may be involved in regulation of BAT activity [26] . Type B natriuretic peptide (BNP), FGF21, and interleukin-6 are released after cold exposure and stimulation of sympathetic nerves leading to upregulation of human and murine BAT thermogenesis [27] [28] [29] . Furthermore, BAT thermogenesis was stimulated by activation of the thyroid axis, insulin signaling, GLP-1, and retinol in humans and animals [26, [30] [31] [32] . In contrast, adiponectin suppressed thermogenesis in mice after cold exposure [33] .
The role of orexin neurons in activation of BAT has been widely explored in animal models [22] [23] [24] [25] . However, it is not clear how the lack of orexin neurons in human patients with type 1 narcolepsy affects the regulation of sympathetic and metabolic activity of BAT. Therefore, the aims of our study were to characterize the sympathetic innervation and metabolic activity of BAT by combining 123 I-MIBG SPECT/CT and 18 F-FDG PET/CT for the visualization of BAT in humans with type 1 narcolepsy to help clarify the effect of orexin neuron deficiency on sympathetic and BAT activity during cold exposure.
Methods

Ethics statement
The Ethics Committee of Copenhagen Region approved the study (H-4-2014-051), and the experiments were conducted according to the Helsinki II Declaration. Patients with narcolepsy and healthy controls were included after obtaining written and oral informed consent.
Study participants
Seven patients diagnosed with type 1 narcolepsy were recruited in the present study. The diagnosis was based on International Classification of Sleep Disorders (ICSD-3) criteria [2] . All patients were examined at the Danish Center for Sleep Medicine, Rigshospitalet, Denmark. Exclusion criteria were the presence of neurological, psychiatric, or medical disorders. Patients were evaluated by neurological examination, Stanford sleep questionnaire, PSG, MSLT, CSF orexin-A levels, and HLA-typing of the DQB1*06:02 locus. HLA typing and orexin-A assay measurements have been described previously [34] . Seven healthy controls were included in the study after recruitment through a web portal for research study volunteers. Healthy individuals were selected by age, weight, and sex equivalent to the enrolled patients. None had a history or symptoms of autoimmune, neurological, sleep, or chronic disorder. They underwent a clinical and neurological examination. All patients and controls in the study were Caucasian.
Physiological measurements
The physiological measurements were performed from 08:00 am to 02:00 pm. Respiratory exchange ratio was calculated as the ratio of V CO2 and V O2 . Energy expenditure was determined by indirect calorimetry (Oxycon Champion, Jaeger, Wuerzburg, Germany) using a ventilated hood system. The average V O2 and V CO2 during the last 10 min of the measurement were used to calculate resting energy expenditure. Peak oxygen uptake was assessed using an electronically braked bicycle ergometer (Lode Excalibur, Groningen, The Netherlands) and indirect calorimetry using a facemask and the breath-by-breath technique. Body composition was determined by DXA-scanning (LUNAR Prodigy Pro, GE Healthcare, Madison, WI, USA), using the medium scan mode and extended research analysis.
Project protocol
The interventions in the protocol including DXA, FDG-PET, and MIBG-SPECT scans, cold exposure, and blood sampling for each patient and control were performed from 08:00 am to 04:30 pm as shown in Figure 1 . After an overnight fast, a DXA scan for body composition was performed. A 2 hr cold exposure period was commenced and F-FDG and after another 2 hr period of cold exposure. Blood samples for determination of hormones and glucose were drawn from all participants before cold exposure and after the first 2 hr cooling period.
BAT distribution and sympathetic activity
123I-MIBG SPECT/CT
All participants dressed in hospital T-shirt and long pants in a room at 22 ± 1°C were exposed to 2 hr of mild cold with both feet placed intermittently (5 min in/5 min out) in cold water at 9 ± 1°C. Shivering was neither reported by participants nor noticed by research staff. After 1 hr of cold exposure, approximately 300 MBq of 123 I-MIBG was administered intravenously and cold exposure was continued for another hour. Thereafter, the participants resided in another room at 22 ± 1°C 3 hr. Subsequently, an upper-body SPECT/CT was acquired at 4 hr after 123 I-MIBG injection. All participants were pretreated with potassium iodide to block the thyroid uptake of 123 I-MIBG. All images were performed using a 16-slice SPECT/CT scanner (Precedence, Philips Medical Systems, The Netherlands) with a low-energy general purpose collimator and a 128 × 128 matrix. A 15 per cent window was set for the main energy peak of 123 I (159 keV). SPECT images were reconstructed with the Philips Astonish technique (OSEM, depth-dependent resolution recovery method). The reconstruction was performed with three iterations and eight subsets as recommended by the vendor. All scans were corrected for attenuation using low-dose CT (no intravenous contrast). In areas in which uptake of 123 I-MIBG was identified by SPECT and the presence of fat was identified by CT (Houndsfield units between −250 and −50), semiquantitative uptake of 123 I-MIBG was calculated as the maximum count per voxel in the volumes of interest (VOIs) divided by the mean count per voxel in a reference region (the mediastinum). Anatomic areas of interest were supraclavicular, cervical, paraspinal, and superior mediastinal depots of adipose tissue. Active BAT was mostly found in the supraclavicular region, but in some cases also in other areas.
18F-FDG PET/CT
All participants were exposed to mild cold for 2 hr as described above. After 1 hr of cold exposure, approximately 200 MBq of 18 F-FDG was administered intravenously and exposure to cold was continued for another hour. Upper body (from the base of the skull to mid femur) static PET acquisition was performed 1 hr after 18 F-FDG injection. PET/CT images were acquired with a Siemens Biograph mCT PET 128-slice scanner (Siemens Medical Solution, Knoxville, TN, USA). A low dose CT (120 kV, 11 mA) for attenuation correction and anatomic localization was performed directly prior to each PET scan. The PET scan protocol consisted of a 4 min per bed scan of the upper body and acquired in list mode. The scan was reconstructed as a single time frame with 336 × 336 pixels, 3 iterations, 21 subsets, and 2 mm Gaussian smoothing. Furthermore, all scans were corrected for attenuation and scatter. In anatomic regions of interest, the presence of fat was identified by CT and a maximal standardized uptake value (SUVmax) of 18 F-FDG, defined as activity in Becquerels per gram of body weight, of at least 2.0 g/mL was considered indicative of BAT [18] [19] [20] . Semiquantitative uptake of 
Biochemical measurements of plasma hormones and glucose
All plasma samples were frozen and stored at −20 o C.
Adiponectin, GLP-1, and interleukin-6 were analyzed with the MSD multiarray electrochemiluminescence immunoassay (Meso Scale Discovery, Rockville, Maryland, USA) with intraassay variation <5 per cent. Insulin, proBNP, and TSH were measured with sandwich electrochemiluminescence immunoassay on COBAS 8000 modular analyzer e602 modul (Roche Diagnostics, F. Hoffmann-La Roche AG, Basel, Switzerland) with intra-assay variation <5 per cent and inter-assay variation 5%-8%. FGF21 was determined with Quantikine ELISA (R&D systems, Abingdon, UK) with intra-assay variation <5 per cent and inter-assay variation <10%-12%. Retinol was determined with Vitamin A/E reverse phase HPLC assay (Bio-Rad Laboratories, Hercules, California, USA) with intra-assay variation <8 per cent and inter-assay variation <12 per cent. Plasma glucose was measured with the hexokinase/glucose-6-phosphate dehydrogenase method on COBAS 8000 modular analyzer c702 modul (Roche Diagnostics, F. Hoffmann-La Roche AG, Basel, Switzerland) with intra-assay variation 1 per cent and interassay variation 3 per cent.
Statistical procedures
The study was based on an a priori power calculation to satisfy our requirements of having at least a power of 70 per cent for demonstrating a significant difference of 60 per cent in the key variables, 123 I-MIBG and 18 F-FDG, between patients and healthy control participants at the 5 per cent level. Calculations were based on reported standard deviations from the literature where a similar setup and timing had been used in normal participant. Accordingly, for 123 I-MIBG at 4 hr, absolute tracer uptake has been reported as 37.4 ± 14.1 counts/VOI and for semiquantitative uptake 1.8 ± 0.51 has been reported [20] . For 18 F-FDG SUV max , the value has been reported as 5.0 ± 2.0 g/mL [21] . With a total of 6 participants in each group, the following powers were obtained for detection of Data were analyzed using SPSS for Windows (SPSS Statistics 22. Inc., Chicago IL, USA). All data are presented as means ± SD. Two-tailed unpaired t-tests were used to test whether respiratory exchange ratio, energy expenditure, lipid oxidation rate, maximal oxygen uptake, and heart rate, as well as BAT uptake of I-MIBG differed between narcoleptic patients and control participants. A mixed model analysis of variance (ANOVA) was used to test whether results concerning hormone levels differed between patients with narcolepsy and control participants (between-participant factor) and before versus after 2 hr cold exposure (within-participant factor). p < 0.05 was considered statistically significant.
Results
Patient characteristics
Each group of patients with type 1 narcolepsy and healthy controls included three females and four males. Patients fulfilled the diagnostic criteria of type 1 narcolepsy according to the International Classification of Sleep Disorders Third edition including cataplexy, fragmented light sleep, higher frequency of sleep-wake transitions, MSLT showing a short time to fall asleep plus REM sleep, positive HLA DQB1*06:02, and orexin-A concentration < 110 pg/mL in the CSF [2] . Five patients had orexin-A in CSF < 10 pg/mL and two patients had CSF orexin-A levels of 35 and 39 pg/mL. These values correspond to less than 10 per cent of the value in healthy controls which have a mean CSF orexin-A value of 429.7 ± 95 pg/mL (mean ± 2 SD) [3] . This leads us to conclude that virtually all neurons might be lost in the patients [35] . The age of patients with type 1 narcolepsy and controls was 28.6 ± 10.1 and 30.1 ± 8.6 years (mean ± SD), and BMI was 28.0 ± 2.0 and 25.7 ± 3.0 (mean ± SD), respectively. Body composition was determined with DXA scanning and the average fat mass was 33.8 ± 11.1% in patients and 30.0 ± 8.2% in controls (p > 0.05). Respiratory exchange ratio, energy expenditure, lipid oxidation rate, maximal oxygen uptake, and heart rate showed no significant differences between patients with type 1 narcolepsy and healthy controls (p > 0.05) ( Table 1) . I-MIBG in BAT of patients with narcolepsy was 1.7 ± 0.8, which was not significantly different from controls 2.5 ± 1.7 (Table 2) . 18 F-FDG PET/CT was performed after 2 hr cold exposure. In anatomic regions of interest, the presence of fat was identified by CT and a SUVmax of 18 F-FDG, defined as activity in Becquerels per gram of body weight, of at least 2.0 g/mL was considered indicative of BAT [18] [19] [20] . BAT was identified by 18 F-FDG PET/CT in the cervical, supraclavicular, and superior mediastinal depots of all patients as shown in Figure 2B . Calculation of the 18 F-FDG PET/CT data showed that the SUVmax of 18 F-FDG was 2.0 ± 0.4 g/ mL in patients with narcolepsy and 3.0 ± 1.8 g/mL in controls, which was not significantly different. The semiquantitative 18 F-FDG-uptake in BAT after 2 hr cold exposure was 0.6 ± 0.1 in patients with type 1 narcolepsy and 1.0 ± 0.7 in healthy controls. This was not significantly different between groups (Table 2) .
Hormones regulating BAT
Hormones involved in regulation of BAT were analyzed before and after 2 hr cold exposure in plasma samples from fasting patients with type 1 narcolepsy and healthy controls (Table 3 ). Mixed-model ANOVA analysis was used to test differences between the hormone levels in patients with narcolepsy versus control participants (between-participant factor) and before versus after 2 hr cold exposure (within-participant factor) (Table 4) . Plasma levels of GLP-1 were significantly higher in patients with type 1 narcolepsy compared with controls determined before cold exposure. Furthermore, FGF21 levels decreased significantly after 2 hr cold exposure in both patients with type 1 narcolepsy and control participants. proBNP, interleukin-6, TSH, insulin, adiponectin, retinol, and plasma glucose concentrations showed no significant differences between patients and controls or within the two groups after 2 hr cold exposure (Table 4) .
Discussion
The present study is the first investigation of BAT activity in human patients with type 1 narcolepsy. The sympathetic activity and glucose uptake in BAT were measured by 123 I-MIBG SPECT/CT and 18 F-FDG PET/CT after 2 hr cold exposure (Figure 3) . The following main results were obtained as follows: (1) The levels of sympathetic and metabolic activity of BAT in patients with narcolepsy were not significantly different from the levels in healthy individuals; (2) FGF21 was significantly decreased after cold exposure in both narcolepsy patients and healthy controls; (3) GLP-1 levels were significantly increased in patients with narcolepsy compared with controls. Our findings suggest that lack of orexin neurons in humans is not accompanied by impaired sympathetic and BAT activity, suggesting that nonshivering thermoregulation is normal. Increased levels of GLP-1 may reflect autonomic dysfunction in type 1 narcolepsy.
Our identification of functional BAT in patients with type 1 narcolepsy raises three issues about the regulation and significance of thermogenesis in narcolepsy, which will be addressed as follows: (1) discrepancy between orexin-deficient narcolepsy in humans and animal models, (2) neural mechanisms of BAT activation in the absence of orexinergic innervation, and (3) hormones and BAT activity in narcolepsy. First, our finding of functional BAT in human narcolepsy differs from a mouse model of narcolepsy. In mice with narcolepsy after ataxin-ablation of orexin-expressing neurons, the BAT thermogenesis induced by cold or stress as well as prostaglandin E 2 was significantly reduced [23, 24] . When the BAT was directly activated by a β3-adrenergic agonist, there was no difference in the resultant temperature response among the groups, indicating that BAT per se was normal in orexin neuron-ablated mice [23] . However, another study reported impaired thermogenesis in orexin gene knock-out mice due to decreased development and differentiation of BAT [36] .
Differences in the destruction of orexin neurons, inflammatory reaction, and compensatory mechanisms in the brain of human type 1 narcolepsy versus narcolepsy in orexin neuronablated mice may account for the differences in sympathetic and thermogenic responses. Type 1 narcolepsy is caused by autoimmunity-mediated destruction of orexin nerve cells in the hypothalamus and orexin axons projecting to several brain regions [1, 4] . In orexin neuron-ablated mice, 99 per cent of orexin neurons were gradually lost during 12 weeks through expression of the neurotoxin ataxin-3 under the control of the human orexin promoter. Nevertheless, these mice exhibited a phenotype strikingly similar to human narcolepsy, including cataplexy-like behavioral arrests, premature onset of REM periods, fragmented wake and non-REM sleep episodes, and increased body weight [37] . Consequently, it remains to be established whether subtle differences in the two phenotypes may exist following the loss of orexinergic neurons.
Species variation in thermoregulation between humans and mice may explain the differences in cold-induced thermogenesis observed in narcolepsy. Murine thermoregulation is preferentially designed to conserve heat, in contrast to human thermoregulation, which is preferentially designed to dissipate heat. Consequently, mice are strongly dependent on activation of BAT thermogenesis during cold exposure in contrast to humans [38] . Furthermore, the estimated amount of BAT in humans is sufficient to account for only 5 per cent of the basal metabolic rate [39] . Another issue to consider is the lower critical ambient temperature, i.e. the environmental temperature at which metabolic heat production is beginning to increase, which for a mouse is ~30 o C compared with 22 o C for a lightly clothed human. Most murine studies therefore seem to be performed under temperature conditions that are matched to human thermoneutral conditions and not to mouse thermoneutral conditions [40] . Second, compensatory neural mechanisms may be involved in cold-induced thermogenesis, sympathetic stimulation, and BAT activity in orexin-A deficient narcolepsy. Activation of histaminergic neurons in the tuberomamillary nucleus (TMN) in the hypothalamus of rats is a critical pathway in the regulation of sleep/wakefulness states [41, 42] . Histamine is also important for regulation of thermogenesis since infusion of histamine into the third cerebral ventricle, and microinjection of histamine into the paraventricular nucleus in hypothalamus of anesthetized rats significantly increased the electrophysiological activity of sympathetic nerves and UCP1 mRNA expression in the interscapular BAT [43] . Two studies have determined the number of histamine neurons in the hypothalamus of patients with narcolepsy and animal models of narcolepsy. In human narcolepsy with cataplexy, the number of histamine neurons in the TMN of the hypothalamus was increased 64 and 94 per cent [44, 45] . The one study also found increased number of histaminergic TMN neurons in orexin neuron-ablated mice and orexin knockout mice [45] , whereas the other study did not see altered numbers Table 2 . BAT activity after cold exposure in patients with type 1 narcolepsy and healthy controls as assessed by PET/CT and SPECT/CT with 18 of histamine cells in any of the animal models of narcolepsy [44] . We speculate that the increase in histaminergic neurons in human narcolepsy may be a compensatory response to loss of excitatory drive from the orexin neurons and may be involved in the activation of BAT in patients with type 1 narcolepsy. It should also be considered that orexinergic neurons contain not only orexin, but also other putative neurotransmitter candidates such as glutamate [46] , dynorphin [47] , galanin [48] , nitric oxide [49] , and neuronal activity-regulated pentraxin (NARP) [50] , which may act synergistically with orexin. Importantly, these cotransmitters were identified in studies of rats raising the possibility that a different expression of colocalized neurotransmitters in human brain may explain the phenotype after the loss of orexinergic neurons with conservation of cold-induced BAT thermogenesis.
Third, our observation that plasma levels of hormones involved in regulation of BAT including proBNP, interleukin-6, TSH, insulin, GLP-1, retinol, and adiponectin are not altered in patients and controls after 2 hr in the cold may indicate that endocrine regulation is not essential in acute nonshivering thermogenesis of BAT in contrast to the nervous regulation mediated by norepinephrine, orexin, histamine, and glutamate [26, 51] . The level of FGF21 decreased after 2 hr cold exposure in both narcolepsy patients and healthy controls. This finding is in contrast with two recent reports that circulating levels of FGF21 correlated with increased BAT activity after acute cold exposure of healthy human individuals [28, 52] . However, these studies applied strong cooling until shivering in contrast to the mild cold exposure in our study. Furthermore, plasma FGF21 exhibited a pronounced diurnal rhythm peaking in the morning and dropping to a nadir in the afternoon, which may confound our measurements [53] . The fasting concentration of GLP-1 was increased in patients with type 1 narcolepsy compared with healthy individuals. Recently, it was reported that fasting GLP-1 levels were increased in patients with severe obstructive sleep apnea and positively correlated with the severity of the disease [54, 55] . Our findings may indicate that fragmented sleep in narcolepsy is associated with increased GLP-1. GLP-1 may induce insulin secretion to control fasting plasma glucose within the normal range in these patients [6, 7] .
There are some limitations concerning study design and implications. First, the present study was powered to detect only major changes regarding key variables in the present study (e.g. FDG uptake in BAT). A power of 70 per cent was chosen as this was an exploratory study. However, if a power of 80 per cent is applied, a difference of 70 per cent can be detected with n = 7 in each group. Due to the size of the standard deviations in the present population and based on the a priori power calculation, we cannot rule out the possibility of smaller differences between groups concerning these variables [56] . Furthermore, the small sample size and modest statistical power in the study may also explain the nonsignificant increase of proBNP between patients and control participants. Second, by using 18 F-FDG PET/CT to identify BAT, we were detecting only the tissue that was actively taking up glucose. Furthermore, the identification of fat by CT and determination of SUVmax of 18 F-FDG by PET were limited to cervical-supraclavicular depots, whereas other locations of BAT were not included in the measurements [57] . Consequently, we did not attempt to determine the actual volume of BAT in our patients and controls. Moreover, the definition of BAT was deliberately very specific, using a high level of activity (SUVmax > 2.0) for the threshold and measuring only the principal depot of BAT in humans found in the cervical-supraclavicular region [58] . However, by evaluating only the most active portion of BAT activity, it cannot be ruled out that BAT metabolism was overestimated by 18 FDG PET in the patients with narcolepsy. Third, the study lacks baseline measurements of BAT activity in the absence of cold exposure, which makes it difficult to draw conclusions on BAT activation. Furthermore, it is unclear whether the cold exposure protocol was adequate to elicit a BAT thermoregulatory response and equally effective in both participant groups. This may have been supported by measurements of energy expenditure and plasma norepinephrine (and ideally also rectal temperature and blood pressure) before and during the cold exposure protocol. However, the 123 I-MIBG uptake in BAT measured by SPECT/CT after cold exposure showed that the sympathetic activity of BAT in patients with narcolepsy was not significantly different from that in healthy individuals. Fourth, it should be noted that patients with narcolepsy during wakefulness may have a relative vasodilation of the distal skin compared with healthy participants [13, 14] . This may have increased the effect of the cold exposure protocol of the present study (feet placed in cold water) in patients with narcolepsy compared with healthy participants. Fifth, the conservation of cold-induced BAT activity in patients with narcolepsy is different from the blunted response in orexin neuron-ablated mice. At present, we cannot link our observation of functional sympathetic and maintained BAT activity in narcolepsy to differences in the pathophysiology of the disease between humans and animal models.
In conclusion, this study demonstrates that sympathetic and BAT activity during cold adaptation is functional in patients with type 1 narcolepsy. This study uncovers for the first time that β-adrenergic activity is maintained in BAT thermogenesis as part of the sympathetic nervous drive in the absence of orexinergic innervation in narcolepsy. 
